Singapore-based MedTech firm Biorithm has successfully closed a $3.5M Series A funding round, co-led by Adaptive Capital Partners and SEEDS Capital, the investment arm of government agency Enterprise Singapore. This funding will support the expansion of Biorithm’s connected pregnancy management solutions in Southeast Asia and the United States. It also will assist the company in advancing Femom, a comprehensive obstetric remote monitoring solution, and completing clinical studies to support a 510(K) premarket submission to the US Food and Drug Administration.
The startup aims to strengthen the women’s health ecosystem by forming key partnerships globally. Biorithm’s flagship product, Femom, is a patient-friendly technology that facilitates monitoring and provides personalized guidance. As Biorithm continues to drive innovation in women’s health, they aim to provide proactive and connected healthcare solutions for expectant mothers, ultimately reducing preventable complications and improving maternal and baby health.
Julian Robinson, Chairman of Biorithm Medical Advisory Board, highlighted the significance of this technology, that will offer enhanced accessibility and improved healthcare outcomes: “Biorithm will enhance care, minimize inconvenience, and reduce cost for patients and improve the efficiency and effectiveness of the clinical health care provider. Above all, it will improve medical outcomes for mothers and their babies.”
“We feel a deep commitment to improving the health of expectant mothers and putting an end to preventable complications. There is a collapse of maternal care driven by socio-economic factors and limitation of current monitoring technologies in many regions across the world, and we are hard at work to solve this problem in partnership with others. The investment we have received is a testament to our mission at Biorithm, and a future where every expectant mother has access to healthcare that is not only proactive but profoundly connected to her unique journey,” said Amrish Nair, Founder and CEO, Biorithm.
Having successfully completed clinical trials with healthcare institutions in Singapore and the United Kingdom, Biorithm will be expanding its clinical trial footprint to more priority markets. Biorithm is also channeling its incoming funding into further research that demonstrates how remote care can be most effectively deployed. In its aim to strengthen the overall women’s health ecosystem, Biorithm will chart out and foster key partnerships with various stakeholders globally to improve maternal and baby health through data, personalized and accessible care.
“Building a system of connected medical care is crucial to help clinicians predict, diagnose, and formulate calculated decisions on early intervention to prevent complications and devise treatments. We are excited with our investment into Biorithm as the company is focused on creating measurable and actionable value in maternal health, integrating this system across all touchpoints to ensure safety throughout the pregnancy journey,” said Shi Ying, Founder & Managing Partner, Adaptive Capital Partners
Tan Kaixin, General Manager, SEEDS Capital added, “By leveraging technology to enable remote monitoring, Biorithm’s offering provides enhanced access to quality care for expectant mothers. We are excited to continue backing Biorithm as they accelerate their commercialization in the US and support their vision of revolutionizing the global maternal health market. Investments in MedTech startups like Biorithm will propel the healthcare ecosystem to new heights.”
